In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Isis: Pondering Platform Power

Executive Summary

The January 2008 collaboration Isis forged with Genzyme was transformative for Isis and a desperately sought-after validation of the antisense field. But unlike its brethren in oligonucleotide drug development -- and most biotechs, for that matter -- Isis rejects the notion of commercializing its products. The deal sets up a paradox: Can Isis remain a platform company once investors' focus is on a product and its trajectory? In a sense, can it stay small?
Advertisement

Related Content

Can Isis Remain A Platform Company?
Celgene Dips Into The Antibody Well Once More, Partners With Sutro
Sirtris Satisfies GSK's M&A Appetite
Archemix Reduces Aperture to Pursue Orphan Diseases
Genzyme/Isis: Has ENHANCE Dulled Mipomersen's Prospects?
Genzyme/Isis: Has ENHANCE Dulled Mipomersen's Prospects?
Alnylam Takes Platform Monetization to a Whole New and Non-Exclusive Level
Alnylam Takes Platform Monetization to a Whole New and Non-Exclusive Level
20% Solution: Addressing the Biotech/Pharma Logjam with Innovation Partnerships
20% Solution: Addressing the Biotech/Pharma Logjam with Innovation Partnerships

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel